Page 8 - 2019-2020 ARCS Oregon Annual Report

8
“Acute Myeloid Leukemia (AML) is the deadliest blood-related malignancy with many patients patients relapsing Current treatments offer only short-term benefits because patients patients patients develop develop drug resistance resistance My research focuses on on understanding why patients patients develop develop resistance resistance Growing evidence illuminates the the the importance of of the the the the bone marrow microenvironment in in in in in in fostering the the the the survival of of leukemia leukemia cells cells cells cells Specifically I examine how the the the the interaction between leukemia leukemia leukemia cells cells cells cells and stromal cells cells cells cells cells in in in in the the the bone marrow enables leukemia leukemia leukemia cells cells cells cells cells to become drug- resistant Understanding what gives the the the the leukemia leukemia cells cells cells a a a a a a a a a a a growth-permissive signal could guide the the the development of new therapies combined with existing inhibitors to to improve patient outcomes My ultimate goal is to to develop a a a a a a a a a productive cancer research laboratory while maintaining an an an an integrated clinical practice at at at an an an an academic medical center I am thankful to ARCS Oregon and and my my donors for for believing in in in my my potential and and for for their unwavering support throughout my PhD training Professional schooling can be very challenging but I am fortunate that even during during my long nights in in in in in the lab or or now now during during a a a a a a a pandemic I I know my ARCS ARCS family is cheering me on I I am am equally thankful and and inspired by the ARCS ARCS community and and scholars ”
Sunil Joshi
School of Medicine Physiology & Pharmacology
OHSU
University Matched Endowment
given by: Kirby & Carl Dyess